Moreover, Variation in a single nucleotide polymorphism in SLC18A2 gene encoding VMAT2 have been implicated in the occurrence of Tardive Dyskinesia (TD) which could potentially give insight on the specific therapeutic target [110]. The gene discussed is SLC18A2; the disease is thanatophoric dysplasia.